EMATOLOGIA

• Tafasitamab in associazione a lenalidomide e r-chop nei pazienti con linfoma diffuso a grandi cellule b (dlbcl) precedentemente non trattato: risultati dello studio di fase 3 frontmind

• Dati iniziali di efficacia e sicurezza dello studio linker-al2 di fase 1/2 su linvoseltamab (linvo) in monoterapia in pazienti con amiloidosi sistemica a catene leggere (al) recidivante o refrattaria (rr)
• Studio di fase 3 randomizzato di talquetamab (tal) più daratumumab (dara) ± pomalidomide (pom) versus daratumumab più pomalidomide e desametasone (dpd) nel mieloma multiplo recidivato/refrattario (rrmm): monumental-3

• Asc4first wk 144 analysis: continued superior efficacy and favorable safety of asciminib vs investigator-selected tyrosine kinase inhibitors in newly diagnosed chronic phase chronic myeloid leukemia
• Frontline asciminib for chronic phase cml: long term safety and efficacy in the allg cm13 ascend trial
• Emotional distress dominates quality of life burden in cml: psychometric validation of patient reported outcomes in a global leukemia experience survey
• How many chronic-phase cml patients starting tyrosine kinase inhibitors can achieve a persistent treatment free remission and be potentially cured? a single center real-life experience
• Asciminib versus second-generation tkis in chronic-phase cml after ≥2 prior tkis: a propensity score-matched analysis
• Risk of permanent frontline discontinuation during the first 36 months of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia: a “campus cml” study with a new “ad hoc” score proposal

• Effect of ianalumab plus eltrombopag on patient-reported outcomes in primary immune thrombocytopenia: results from the vayhit2 phase 3 trial
• Effects of ianalumab treatment on b cell activation, maturation, and maintenance of vaccine titers in patients with primary immune thrombocytopenia in the phase 2 vayhit3 study

• Evaluation of pelabresib (pela) as add-on therapy to janus kinase inhibitor (jaki) ruxolitinib (rux) in myelofibrosis (mf) patients: results from arm 2 of the open-label, phase 2 manifest study
• Pelabresib monotherapy in myelofibrosis after janus kinase inhibitor failure: results from arm 1 of the open-label, phase 2 manifest study
• Real world outcomes of treatment with ruxolitinib for polycythaemia vera patients at a single centre district general hospital

• Tisagenlecleucel in pediatric and young adult patients with high-risk b-cell acute lymphoblastic leukemia and minimal residual disease at the end of frontline consolidation
• Pet-integrated nomograms for survival prediction in patients with large b-cell lymphoma treated with car t-cell therapy
• International expert consensus on real-world car t-cell eligibility in large b-cell lymphomas: an e-delphi study
• Radiotherapy as bridging, salvage or consolidation strategy in car-t–treated lymphoma patients: insights from the french descar-t registry
• Nutritional parameters  as prognostic markers in older patients with diffuse large b-cell lymphoma: a post-hoc analysis of the elderly project by fondazione italiana linfomi

• Iptacopan demonstrates sustained efficacy and safety in paroxysmal nocturnal hemoglobinuria: up to 4 years of follow-up in patients from apply, appoint and roll-over extension program
• Consistent and sustained efficacy and safety of iptacopan in paroxysmal nocturnal hemoglobinuria regardless of prior history of major adverse vascular events in apply, appoint and extension program
• Real-world outcomes of iptacopan in paroxysmal nocturnal hemoglobinuria (pnh) patients: insights from the french early access program.
• Long-term hematologic control and safety in patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan: 6-year follow-up from phase 2 studies and roll-over extension program
• Long-term safety with iptacopan treatment in patients with paroxysmal nocturnal hemoglobinuria (pnh): pooled analysis of data from phase 2 and 3 studies and the roll-over extension program
• Clinical burden of pnh patients with hemoglobin between ≥10 and <12 g/dl: results from a multinational real-world study

• Asciminib for relapsed or refractory philadelphia-positive acute lymphoblastic leukemia (ph+ all) and lymphoid blast crisis of chronic myeloid leukemia (lbc-cml) in italy: a campus all real life study

• Distinct patterns of mutant asxl1 over time and their implications for treatment failure (tf) and bcr::abl1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (cml-cp) treated with asciminib (asc) vs investigator-selected tyrosine kinase inhibitors (is-tki) in the asc4first study
• Asciminib (asc) demonstrates continued improvement in patient-reported outcomes (pros) vs investigator-selected tyrosine kinase inhibitors (is-tkis) in newly diagnosed chronic myeloid leukemia (cml): asc4first week 96 analysis
• Improved long-term tolerability with asciminib (asc) vs investigator-selected (is) tyrosine kinase inhibitors (tkis) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (cml-cp): week 96 exploratory analysis of the phase 3 asc4first trial
• Treatment cost per ae symptom-free day of asciminib and second-generation tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia
• Indirect treatment comparison (itc) of asciminib and dasatinib in newly diagnosed chronic myeloid leukemia in chronic phase (cml-cp)
• Asciminib (asc) in chronic myeloid leukemia in chronic phase (cml-cp): interim analysis (ia) efficacy and safety results of the phase 2 asc2escalate trial in the cohort of newly diagnosed (1l) patients (pts)
• A comparison of real-world outcomes of asciminib versus atp-competitive tyrosine kinase inhibitors as second-line treatment in patients with chronic myeloid leukemia in chronic phase
• Asciminib (asc) in chronic myeloid leukemia in chronic phase (cml-cp): efficacy and safety results of the phase 2 asc2escalate trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (tki)
• Asc4opt 96-week results: asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors

• End-of-study results from the icon3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
• Primary results from vayhit2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (itp) who failed first-line corticosteroid treatment

• It’s not yet time to abandon ruxolitinib in anemic myelofibrosis: predictive factors of erythroid response to standard anemia-directed therapies combined with ruxolitinib
• Durable efficacy and long-term safety with pelabresib plus ruxolitinib in jak inhibitor–naive myelofibrosis: 96-week results from the phase iii manifest-2 study
• Real-world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis: an analysis of the medicare fee-for-service claims database
• Changes in neutrophil-to-lymphocyte ratio (nlr) in patients with polycythemia vera treated with ruxolitinib reflect changes of jak2 variant allele frequency (vaf)
• Ruxolitinib duration of treatment and effect on phlebotomy use among 2369 patients with polycythemia vera: a real-world analysis of the medicare fee-for-service claims database

• Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r fl): phase 2 elara 5-year update
• Health-related quality of life trajectories of patients with aggressive b-cell lymphomas treated with car t-cell therapy: results from a prospective observational study
• The prognostic value of patient-reported fatigue for survival in patients with aggressive b-cell lymphomas treated with car t-cell therapy

• Long-term safety and efficacy of iptacopan in patients with paroxysmal nocturnal hemoglobinuria: 4- and 5-year follow-up of patients from phase 2 studies who entered the roll-over extension program
• Iptacopan monotherapy demonstrated improved clinical outcomes in a real-world cohort with paroxysmal nocturnal hemoglobinuria: evidence from a managed access program
• Real-world breakthrough hemolysis patterns across 1,723 patient-years of complement inhibition in paroxysmal nocturnal hemoglobinuria
• The 2-year efficacy and safety of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria with a history of aplastic anemia on concomitant immunosuppressive therapy who entered the roll-over extension program
• Apply-pnh: analysis of complement pathway biomarkers provides evidence for pharmacodynamic response in pnh patients who receive oral iptacopan monotherapy versus continuing anti-c5 therapy
• Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin increases in patients with paroxysmal nocturnal hemoglobinuria with baseline hemoglobin levels 10 to <12 g/dl on anti-c5 therapy: subgroup analysis of the appulse-pnh phase 3b trial

• An integrative prognostic model for transplant outcomes in myelofibrosis
• Impact of ruxolitinib on corticosteroid treatment patterns in 1147 patients with chronic graft-versus-host disease in real-world practice in the united states: a long-term follow-up analysis
• Peri-transplant ruxolitinib therapy significantly improves gvhd-free, relapse-free survival rates in transplantation for myelofibrosis

• Pirtobrutinib vs bendamustina più rituximab (br) in pazienti con cll/sll: primi risultati di uno studio randomizzato di fase iii, esame di un inibitore btk non covalente in pazienti non trattati
• Pirtobrutinib vs ibrutinib nel trattamento della cll/sll naïve e recidivante/refrattaria: risultati del primo studio randomizzato di fase iii che confronta un inibitore btk non covalente e uno covalente

• Asciminib (asc) provides superior efficacy and excellent safety and tolerability vs tyrosine kinase inhibitors (tki) in newly diagnosed chronic myeloid leukemia (cml) in the pivotal asc4first study
• Improved patient-reported outcomes (pros) with asciminib (asc) vs investigator-selected tyrosine kinase inhibitors (is-tkis) in newly diagnosed chronic myeloid leukemia (cml): asc4first wk 48 analysis
• Interim analysis (ia) results from asc2escalate support asciminib (asc) as a treatment (tx) option in chronic-phase chronic myeloid leukemia (cml-cp) after 1 tyrosine kinase inhibitor (tki)
• Asc4opt study: high efficacy and favorable tolerability of asciminib once or twice daily in cml patients with suboptimal response, resistance or intolerance of 2 or more tyrosine kinase inhibitors

• 4-year update of phase 2 elara trial: clinical outcomes of tisagenlecleucel in patients (pts) with high-risk relapsed/refractory follicular lymphoma (r/r fl)
• Tisagenlecleucel versus mosunetuzumab in relapsed/refractory follicular lymphoma: an updated matching-adjusted indirect comparison (maic) analysis after 3-year follow-up data
• Rapcabtagene autoleucel (ytb323) in patients with relapsed/refractory diffuse large b-cell lymphoma: a phase ii trial clinical update

• Ianalumab' s dual mechanism of action: targeting b cells through enhanced b-cell depletion and blockade of b cell-activating factor receptor signaling
•  
• A phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy (vayhit3)
• Retrospective review of compliance with international guidelines for immune thrombocytopenia (itp): strategies for improving diagnostic and therapeutic approaches
• Factors influencing the choice of romiplostim or eltrombopag in immune thrombocytopenia: insights from a real-world european cohort
• Changes in diagnostic approaches and tpo-ra utilization before and after 2010: insights from a multicenter european cohort

• Clinical outcomes in patients with myelofibrosis treated with ruxolitinib and anemia supporting medications
• Impact of eln clinical signs and symptoms on outcomes in polycythemia vera patients treated with hydroxyurea or ruxolitinib: a cooperative study
• Pelabresib in combination with ruxolitinib for janus kinase inhibitor-naive patients with myelofibrosis: 72-week follow-up with long-term efficacy outcomes of the phase iii manifest-2 study
• Retrospective analysis of efficacy and safety outcomes in patients with primary and secondary myelofibrosis treated with ruxolitinib: jump study
• Clinical pathways and prognostic strategies in myelofibrosis: a real-world analysis of german practice
• Health-related quality of life and symptom burden in pre-fibrotic and overt myelofibrosis compared to the general population and physician perceptions: results from the gimema-prophecy study
• A delphi consensus to define disease progression and disease modification in polycythemia vera 
• Lymphocyte to monocyte ratio may predict transformation to myelofibrosis for polycythemia vera patients treated with ruxolitinib: experience from majic-pv trial

• Effectiveness and safety of iptacopan in paroxysmal nocturnal hemoglobinuria patients with persistent anemia after c5 inhibition: the real-world experience of the french early access program
• The 2-year safety and efficacy of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria (pnh) from apply- and appoint-pnh studies who entered the roll-over extension program (rep)
• Appulse-pnh: oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin (hb) increases in patients (pts) with paroxysmal nocturnal hemoglobinuria (pnh) and hb ≥10 g/dl on anti-c5 therapy
• Obtaining insights on pnh management with iptacopan in everyday clinical practice: a research collaboration with the ipig pnh registry
• Prophylaxis and management of thromboembolism in pnh patients: an italian survey
• The daily impact of fatigue in paroxysmal nocturnal haemoglobinuria (pnh): an ethnographic study
• Systematic mapping of paroxysmal nocturnal hemoglobinuria resources: identifying gaps in clinical education tools to improve diagnosis and patient care
• A single center real-world analysis: clinical characteristics and prediction of thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria
• Indirect treatment comparison of iptacopan vs. pegcetacoplan in complement inhibitor naïve paroxysmal nocturnal hemoglobinuria patients
• Network meta-analysis comparing the efficacy of different complement pathway inhibitors for the treatment of paroxysmal nocturnal hematuria
• Real-world outcomes and clinical burden of patients with paroxysmal nocturnal hemoglobinuria

• Treatment with asciminib as a second line after one prior tyrosine kinase inhibitor (tki) in patients with chronic-phase chronic myeloid leukemia (cml-cp) – a chart review study in the united states
• Asciminib (asc) demonstrates favorable safety and tolerability compared with each investigator-selected tyrosine kinase inhibitor (is tki) in newly diagnosed chronic myeloid leukemia in chronic phase (cml-cp) in the pivotal phase 3 asc4first study
• Update of the ascend-cml study of frontline asciminib: high rate of optimal response and resistance due to mutations is rare
• Asc4real: efficacy and tolerability comparison between ascembl study, a phase 3 randomized clinical trial (rct), and consolidated real-world (rw) evidence with asciminib in cml patients beyond 2 tkis
• Asciminib shows high efficacy and favorable tolerability at 80 mg once daily and 40 mg twice daily in patients with chronic phase chronic myelogenous leukemia previously treated with 2 or more tyrosine kinase inhibitors: primary analysis from the asc4opt study

• Efficacy and safety of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma: a real-world analysis from the center for blood and marrow transplant research (cibmtr) registry
• Clinical outcomes of patients with high-risk relapsed/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 elara 4-year update
• A swot-consensus for car-t in follicular lymphoma: fine tuning of patient journey and selection

• Real-world ruxolitinib and corticosteroid treatment patterns in patients with chronic graft-versus-host disease in the united states
• Serial clinical and biomarker monitoring during treatment can stratify patients with low risk gvhd
• Identification of high-risk patients and establishment of a clinical prediction model for frontline steroid failure in chronic graft-versus-host-disease
• Age is a crucial determinant of gfrs with incidence of severe chronic gvhd reducing over time in haemopoietic cell transplantation for transfusion dependent thalassaemia: real world data from 2010-2021. an analysis of the european society for blood and bone marrow transplantation hemoglobinopathy working party

• A phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy: interim results from vayhit3s
•  

• Clinical outcomes in patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications
• Clinical and molecular characterization of disease progression in patients (pts) with low-risk myelofibrosis (mf) enrolled in the most study
• Molecular predictors of disease progression to myelofibrosis (mf) in patients (pts) with polycythemia vera (pv) enrolled in reveal
• Revised eln criteria in polycythemia vera identify an increased risk phenotype for thrombotic events beyond conventional risk stratification. a multicenter cooperative study
• Real-world treatment patterns and blood count control in patients with polycythemia vera who switched from hydroxyurea to ruxolitinib
• Thrombosis risk assessment in polycythemia vera (trap): a 4,636-patient-year analysis of arterial and venous thrombosis in low-risk patients
• Updated results from the phase 3 manifest-2 study of pelabresib in combination with ruxolitinib for janus kinase inhibitor–naïve patients with myelofibrosis
• Treatment of myeloproliferative neoplasms with janus kinase inhibitors: a meta-analysis of cardiovascular safety
• Outcomes are similar for combination interferon and ruxolitinib versus ruxolitinib in myelofibrosis: a propensity-score matched study
• A predictive model for progression to overt primary myelofibrosis in early/prefibrotic primary myelofibrosis patients
• Understanding the lived experience of fatigue in adolescents and young adults with myeloproliferative neoplasms: a mixed methods study
• Prognostic implications of pulmonary hypertension in myeloproliferative neoplasms and predictors of hematologic progression

• Oral iptacopan monotherapy leads to long-term improvements in patient (pt)-reported health-related quality of life (hrqol) and investigator-assessed signs and symptoms of paroxysmal nocturnal hemoglobinuria (pnh): 48-week (wk) results from the phase iii apply-pnh and appoint-pnh trials
• The effect of oral iptacopan monotherapy on hematological parameters in patients with paroxysmal nocturnal hemoglobinuria (pnh) is consistent regardless of the type of prior anti-c5 treatment received: a post hoc analysis of 24-week data from the randomized phase iii apply-pnh trial

• Asciminib (asc) provides superior efficacy and excellent safety and tolerability vs tyrosine kinase inhibitors (tki) in newly diagnosed chronic myeloid leukemia (cml) in the pivotal asc4first study
• Asciminib as initial therapy for patients with chronic myeloid leukemia in chronic phase (alertcml)
• Treatment patterns and real-world clinical outcomes of patients with chronic myeloid leukemia in chronic phase treated with asciminib in oncology practices in the united states
• Asciminib (asc) is well tolerated in pediatric patients with chronic myeloid leukemia in chronic phase (cml-cp): interim pharmacokinetics and safety results from asc4kids
•  
• Chronic myeloid leukemia survey on unmet needs (cml sun): united kingdom findings on balancing tolerability and efficacy goals of patients and physicians through shared treatment decision-making

• Clinical outcomes of patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 elara 3-year follow-up
• Long-term durable responses in patients with r/r all, dlbcl, and fl treated with tisagenlecleucel and its association with persistence of chimeric antigen receptor (car) t-cells

• Effectiveness of oral ruxolitinib for acute gvhd prophylaxis after haploidentical bone marrow transplantation in patients with severe aplastic anemia: a phase ⅱ,single-center, singlecohort, prospective clinical trial

• Steroids vs eltrombopag for first and second-line treatment of adult immune thrombocytopenia
• Managing chemotherapy-induced thrombocytopenia (cit) with eltrombopag; a retrospective real-world analysis
• Effects of oral iptacopan monotherapy, including increased paroxysmal nocturnal hemoglobinuria red blood cell clone size, are maintained in complement inhibitor-naïve patients: final appoint-pnh data
• Patient experience of iptacopan in three clinical trials for paroxysmal nocturnal hemoglobinuria
• Effects of oral iptacopan monotherapy, including increased paroxysmal nocturnal hemoglobinuria red blood cell clone size, are sustained in anti-c5-treated patients with anemia: final applypnh data
• Breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria treated with complement inhibitors: a multicenter international study
• Understanding the relationship between hemoglobin, fatigue and health-related quality of life for patients with paroxysmal nocturnal hemoglobinuria (pnh)

• Ruxolitinib starting dose reduction affect overall survival in myelofibrosis: aifa monitoring registries analysis
• Patient characteristics, treatment patterns, and health outcomes in a real-world population of patients with myelofibrosis treated with fedratinib
• Deciphering the predictors of death in polycythemia vera: focus on the neutrophil to lymphocyte ratio (nlr) and the incidence of arterial thrombosis
• Comparison between pretranplant, peritransplant and no jak inhibition on outcome after hematopoietic cell transplant for myelofibrosis
• Age-dependent link between arterial thrombosis and secondary cancer in ph-neg mpn: case-control study insights
• Real-world data on direct oral anticoagulants in bcr:abl1- negative myeloproliferative neoplasms: a multicenter study on behalf of subcommittee on mpns for turkish society of hematology
• Health-related quality of life in italian patients with philadelphia-negative myeloproliferative neoplasms compared to the general population: gimema prophecy study
• Revised “irr6” model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib
• Analysis of cardiovascular risk in 920 patients with myeloproliferative neoplasms using natural language processing
• A real-world evaluation of risk factors for disease progression in patients with polycythemia vera (pv) enrolled in reveal
• The triple a model-aaa (age, absolute neutrophil count, absolute lymphocyte count) predicts survival and thrombosis in polycythemia vera
• Ruxolitinib treatment in patients with polycythemia vera reduces jak2 allele burden and improves hematocrit control and symptom burden